Evidence map›Paper›PMID 31839484›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2020

RETRACTED: METTL14 Suppresses CRC Progression via Regulating N6-Methyladenosine-Dependent Primary miR-375 Processing

Xiaoxiang Chen, Mu Xu, Xueni Xu, Kaixuan Zeng, Xiangxiang Liu, Li Sun, Bei Pan, Bangshun He, Yuqin Pan, Huiling Sun and 2 more

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 122 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 1 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 1 synthesis or guideline pooled it, 178 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Aberrant RNA mCell death & disease · 2023
    Review
  13. N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  14. Article
  15. Emerging Regulatory Mechanisms of NPhenomics (Cham, Switzerland) · 2023
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. mCell death & disease · 2022
    Article

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Xiaoxiang ChenGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China; School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China.
Mu XuGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China.
Xueni XuGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China; School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China.
Kaixuan ZengGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China; School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China.
Xiangxiang LiuGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China.
Li SunDepartment of Laboratory Medicine, The Second Affiliated Hospital of Nanjing, Medical University, Nanjing 210011, Jiangsu, China.
Bei PanGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China.
Bangshun HeGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China.
Yuqin PanGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China.
Huiling SunGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China.
Xinyi XiaInstitute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, Jiangsu, China. Electronic address: xiaxynju@163.com.
Shukui WangGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China. Electronic address: sk_wang@njmu.edu.cn.
Nanjing Medical University · CNNanjing University · CNSecond Affiliated Hospital of Nanjing Medical University · CNSoutheast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenosineAnimalsCell Line, TumorColorectal NeoplasmsDisease Models, AnimalDisease ProgressionGene Expression Regulation, NeoplasticGenes, ReporterHumansMethyltransferasesMiceMicroRNAsRNA InterferenceXenograft Model Antitumor AssaysAdenosineMethyltransferasesMETTL14 protein, humanMicroRNAsMIRN375 microRNA, humanN-methyladenosinecolorectal cancermethyltransferase-like 14METTL14N6-methyladenosineprimary miR-375

Identifiers

PMID31839484
PMCPMC7001002
OpenAlexW2991008732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.